CRISPR Therapeutics achieved a major milestone with the approval of its first therapy, Casgevy, for sickle cell disease and beta-thalassemia. The success of Casgevy demonstrates the viability of the company’s strategy. While facing challenges like complex manufacturing and high costs, CRISPR Therapeutics is making progress with securing reimbursements and activating authorized treatment centers. The company’s future success will depend on delivering consistent clinical and regulatory wins, especially with its leading candidate, CTX310. Investing in CRISPR Therapeutics carries risk but also significant upside potential if the company can successfully launch new products in the next few years.

Read more at Nasdaq: Here’s How This Forgotten Healthcare Stock Could Generate Life-Changing Returns